Kronos Bio Inc. Stock News

Kronos Bio, Inc. (NASDAQ:KRON) Director Backer Marianne De acquired 1,150 shares of the stock in a transaction dated Wednesday, December 1st. The shares were bought at an average price of $11.57 per share, for a total transaction of $13,305.50. The acquisition was disclosed in a document filed with the SEC, which is accessible through this []

Initial data demonstrate long plasma half-life and dose-dependent target inhibition

Shares of Kronos Bio, Inc. (NASDAQ:KRON) hit a new 52-week low during trading on Wednesday . The company traded as low as $12.85 and last traded at $12.85, with a volume of 435 shares trading hands. The stock had previously closed at $13.34. A number of equities analysts have recently issued reports on KRON shares. []

Kronos Bio Inc. (NASDAQ:KRON) shares, rose in value on Wednesday, 11/24/21, with the stock price down by -1.80% to the previous days close as strong demand from buyers drove the stock to $13.10. Actively observing the price movement in the last trading, the stock closed the session at $13.34, falling within a range of $12.64 Is Kronos Bio Inc. (NASDAQ: KRON) A Suitable Stock For New Investors Today? Read More »

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced th

California State Teachers Retirement System grew its position in shares of Kronos Bio, Inc. (NASDAQ:KRON) by 136.6% during the second quarter, HoldingsChannel reports. The institutional investor owned 53,517 shares of the companys stock after buying an additional 30,898 shares during the quarter. California State Teachers Retirement Systems holdings in Kronos Bio were worth $1,282,000 as []

Nuveen Asset Management LLC raised its position in shares of Kronos Bio, Inc. (NASDAQ:KRON) by 203.1% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 161,915 shares of the companys stock after purchasing an additional 108,487 shares during the quarter. Nuveen Asset Management LLC []

Squarepoint Ops LLC acquired a new stake in Kronos Bio, Inc. (NASDAQ:KRON) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 28,137 shares of the companys stock, valued at approximately $674,000. Squarepoint Ops LLC owned approximately 0.05% of Kronos Bio at the []

Preliminary clinical data from Phase 1/2 study still anticipated in Q4 Preliminary clinical data from Phase 1/2 study still anticipated in Q4

Announced FDA clearance of Investigational New Drug application (IND) for lanraplenib (LANRA) for treatment of patients with acute myeloid leukemia (AML)

Company intends to develop LANRA as a once-daily chronic treatment for genetically-defined AML patients

Kronos IPO'd in October.

MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON) today commented on the passing of John C. Martin, Ph.D., board member and early investor in t